Related Content
- New alliance will crack down on adulterated products touting dietary supplement claims
- Genentech granted supplemental approval for Actemra
- FDA releases annual 'Generic Drug Roundup'
- FDA approves test to monitor levels of Zortress in the bloodstream
- FDA approves Novartis drug for high blood pressure treatment
SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.
The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.
"People with moderately to severely active RA can suffer irreversible joint damage that may be prevented by earlier treatment with a biologic medicine such as Actemra," Genentech chief medical officer and head of global product development Hal Barron said. "We're pleased that these patients will now have Actemra as an additional option."
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
Comments
Post a CommentThe drug was already approved
The drug was already approved for systemic juvenile idiopathic arthritis. Office Furniture UAE
This is an interesting and so
This is an interesting and so well maintained blog. Whole article is too good and well written.investment in realestate with realestatepatron.com
Perfect piece of writing rich
Perfect piece of writing rich in information. I have been looking for such a post for a long time.
tyvek wristbands
I surprised with the analysis
I surprised with the analysis you made to make this particular publish incredible. Wonderful activity!genemedics.com